Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
ITM Solucin GmbH · Somatostatin Receptor Positive · NETs
Phase 1
Recruiting
20
2026-05
Industry sponsor intelligence
ITM Solucin GmbHClinical Pipeline.
Lead-sponsor view of ITM Solucin GmbH's indexed peptide studies, development phases, active programs, completed work and recent registry changes.
- Total
- 3
- Recruiting
- 1
- Active
- 2
- Completed
- 0
- Results posted
- 1
- Avg enrollment
- 201
Pipeline overview
Programs by phase and activity.
Velocity
ITM Solucin GmbH trials by start year
Study start year · indexed snapshot
Development
Trials by phase
3phase labels
Early Phase 10
Phase 11
Phase 20
Phase 32
Phase 40
| Product | Studies | Early / I | Phase II | Phase III | Phase IV | Active |
|---|---|---|---|---|---|---|
| Octreotide → | 3 | 1 | 0 | 2 | 0 | 3 |
Active peptide trials
In motion now.
NCT IDStudyPhase / statusEnrollmentUpdated
Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients
ITM Solucin GmbH · Neuroendocrine Tumors
Phase 3
Active, not recruiting
324
2026-04
Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE
ITM Solucin GmbH · Neuroendocrine Tumors
Phase 3
Active, not recruiting
259
2025-09
Completed trials
Finished registry records.
No studies in this snapshot.
Search sponsor records
All ITM Solucin GmbH studies.
This page groups studies where ITM Solucin GmbH is listed as the lead industry sponsor. Collaborator-only records are not included in the count.
3 matching studies
Last registry update first
Recent updates
Latest registry movement.
NCT06441331Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive TumorsMay 1, 2026NCT03049189Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET PatientsApr 6, 2026NCT04919226Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSESep 10, 2025